Cronos Group Inc.
Cronos Group Inc. functions as a diversified global cannabinoid enterprise operating within the healthcare sector and the drug manufacturers, specialty & generic industry. Headquartered in Toronto, Canada, the company was established in 2012 and is listed on the TSX. Within the United States, it manufactures,…
Company description based on the data provider's company data, AI-assisted, created on 16/10/2026. Not investment advice.
1D
+0.4%
1W
-1.3%
1M
-1.3%
6M
+23.2%
YTD
+26.7%
1Y
+31.4%
2Y
+52.5%
5Y
-32.6%
10Y
+286.4%
Next earnings date
05/11/2026 (in 19 days)
Volatility around earnings
~17% weaker price swings than usual
0
STRONG BUY
3
BUY
6
HOLD
3
SELL
0
STRONG SELL
12
TOTAL · Hold
As of: 15/05/2024
P/E
17.17
P/B
1.13
EV/EBITDA
13.32
RETURN ON EQUITY
3.0%
NET MARGIN
60.5%
DEBT/EQUITY
0
DIVIDEND YIELD
0.0%
AS OF
30/06/2026
FREE FLOAT
50.8%
FLOAT SHARES
186,987,949
AVG. DAILY VOLUME (30D)
93,096
Cronos Group Inc. is a company in the Healthcare sector, Drug Manufacturers - Specialty & Generic industry, headquartered in Canada.
The CEO is Michael Ryan Gorenstein, the company employs around 610 people.
The IPO was on 17/12/2014; the stock trades on TSX under the ticker CRON.TO.
12 analysts rate the stock, the consensus is Hold (as of 15/05/2024).
This is an external assessment, not a statement by Market Jury.
The next earnings date is 05/11/2026.
Around past earnings, price swings were roughly -17% stronger than usual.
No, Cronos Group currently does not pay a dividend.
Comparable stocks include Merck, Takeda Pharmaceutical Company, Teva Pharmaceutical Industries, Zoetis, Sandoz Group, Viatris, Lantheus Holdings and Amneal Pharmaceuticals.
Clicking "Analyze stock" lets five strategies assess Cronos Group against fixed, published rules and judge it bullish, neutral or bearish. The jury states where it disagrees. A free account starts with 5 credits, a quick check costs 1 credit, a full analysis 2 credits.
Not investment advice. Past performance is not an indicator of future results.